The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.

Background: Despite its high prevalence, optimal therapy for diastolic heart failure (DHF) has not been determined. Alagebrium chloride (ALT-711) is a novel compound that breaks glucose crosslinks and may improve ventricular and arterial compliance.Methods and Results: A total of 23 patients, mean a...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Cardiac Failure Vol. 11; no. 3; pp. 191 - 196
Autores principales: Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC, Little, William C, Zile, Michael R, Kitzman, Dalane W, Hundley, W Gregory, O'Brien, Terrence X, Degroof, Robert C
Formato: diagnostic images pictorial research tables/charts Journal Article
Publicado: W B Saunders 2005 Apr
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106417228&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106417228
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10719164
        DOP
      jtl: Journal of Cardiac Failure
      issn: 10719164
      maglogo: N
    pubinfo:
      dt: 2005 Apr
      vid: 11
      iid: 3
      pid: 1351
      pub: W B Saunders
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        106417228
        106417228
        NLM15812746
        2009130270
        NLM15812746
        106417228
      ppf: 191
      ppct: 5
      formats:
      tig:
        atl: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
      aug:
        au:
          Little WC
          Zile MR
          Kitzman DW
          Hundley WG
          O'Brien TX
          Degroof RC
          Little, William C
          Zile, Michael R
          Kitzman, Dalane W
          Hundley, W Gregory
          O'Brien, Terrence X
          Degroof, Robert C
        affil: Department of Internal Medicine, Cardiology Section, Wake Forest University Health Sciences, Medical Center Boulevard, Winston-Salem, NC 27157, USA
      sug:
        subj:
          Cardiotonic Agents Therapeutic Use
          Diastole
          Glucose Drug Effects
          Heart Failure Drug Therapy
          Aged
          Clinical Assessment Tools
          Data Analysis, Statistical
          Descriptive Statistics
          Female
          Funding Source
          Health Status Indicators
          Heart Atrium Drug Effects
          Heart Ventricle Drug Effects
          Magnetic Resonance Imaging
          Male
          New Jersey
          Nonexperimental Studies
          North Carolina
          Prospective Studies
          Questionnaires
          South Carolina
          Human
          Aged: 65+ years
          Female
          Male
      ab: Background: Despite its high prevalence, optimal therapy for diastolic heart failure (DHF) has not been determined. Alagebrium chloride (ALT-711) is a novel compound that breaks glucose crosslinks and may improve ventricular and arterial compliance.Methods and Results: A total of 23 patients, mean age 71 years, with stable DHF, ejection fraction (EF) >50%, were enrolled in a 16-week, open-label trial of alagebrium 420 mg per day. Assessments included: peak exercise oxygen consumption, aortic distensibility, and left ventricular EF and mass by magnetic resonance imaging, Doppler diastolic filling, and quality of life by the Minnesota Living with Heart Failure questionnaire. One patient discontinued treatment because of a myocardial infarction after 12 days of treatment, and a second died suddenly after 10 weeks of treatment. Thus 21 patients completed the study. Left ventricular mass was 124 +/- 35 g at baseline and decreased to 119 +/- 34 g at follow up ( P = .036). This was accompanied by a decrease in the ratio of Doppler early diastolic flow velocity to Doppler early diastolic mitral annulus velocity (E') from 10.6 +/- 2.7 to 9.4 +/- 1.9 ( P = .076) and an increase in E' from 7.3 +/- 1.2 to 8.4 +/- 1.7 cm/s ( P = .045). The Minnesota Living with Heart Failure total score improved from 41 +/- 21 to 32 +/- 21 ( P = .01). There were no changes in EF (64 +/- 4% at baseline), blood pressure, peak exercise oxygen consumption, and aortic distensibility.Conclusion: Sixteen weeks of treatment with the glucose crosslink breaker, alagebrium, resulted in a decrease in left ventricular mass and improvements in left ventricular diastolic filling and quality of life in patient with DHF.
      pubtype: Academic Journal
      doctype:
        diagnostic images
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N